NYSE:NVO News 18 August 2025

Bitcoin Blasts Past $125K, AI Wars Escalate, and Space Tech Soars – Global Tech Roundup (Oct 5–6, 2025)

Artificial Intelligence (AI) OpenAI vs. Musk’s xAI – legal battle heats up: The Silicon Valley rivalry between Elon Musk and OpenAI turned into open warfare in court. Musk’s AI startup xAI sued OpenAI, accusing it of poaching staff to steal

6 October 2025

Tariff Shocks & Rate Jitters Ignite Wild 48 Hours in European Markets

Key Facts German DAX index graph at the Frankfurt Stock Exchange, reflecting volatile mid-week trading reuters.com. Pan-European Overview: From Slump to Rebound European equities seesawed over the two days, buffeted by transatlantic trade tensions and shifting rate expectations. On Thursday

26 September 2025

Economic News · European Markets · Interest Rates · NYSE:AZN · NYSE:NVO · NYSE:NVS · Stock Market · Tariffs

Weekend Science Bonanza: Breakthroughs From Space to Superbugs

Space & Astronomy Humanity’s search for cosmic neighbors hit a celebratory peak. NASA announced it has confirmed over 6,000 exoplanets – planets orbiting other stars – just three decades after finding the very first such world entechonline.com. This tally reflects

21 September 2025

Medical Research · NYSE:NVO · Science News · Space · Space Exploration · Technology Trends · Weekend Reads

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly’s Weight-Loss Pill Sheds Pounds Fast—But Hits a Plateau: What New Trial Results Mean for the Obesity Drug Race

Trial Results: Big Early Losses, Then Weight Loss Levels Off This highly anticipated trial put Lilly’s oral GLP-1 drug, orforglipron, to the test in a large group of adults struggling with obesity. The study enrolled 3,127 overweight or obese participants

17 September 2025

Clinical Trials · Eli Lilly · NYSE:LLY · NYSE:NVO · Obesity Drugs · Pharma News · Weight Loss

Ozempic for Alzheimer’s? How GLP-1 Weight-Loss Drugs Could Fight Neurodegenerative Diseases

GLP-1 Receptor Agonists and Neurodegenerative Diseases in 2025 GLP-1 receptor agonists like semaglutide (Ozempic®) are typically given via a weekly injection pen. Originally developed for diabetes and obesity, these drugs are now being studied for their effects on the brain.

10 September 2025

Alzheimer’s · GLP-1 Drugs · Medicine · Neurodegenerative Diseases · NYSE:NVO · Weight Loss

Glowing Planets, Monster Blooms & a ‘Next Ozempic’ – Science Highlights (Sept 1–2, 2025)

Space and Astronomy Baby Planet Still Glowing: In a landmark observation, astronomers directly imaged an infant planet still hot from its birth. The gas giant WISPIT 2b, roughly five Jupiters in mass and only ~5 million years old, was discovered orbiting within

2 September 2025

Astronomy · Innovation · Medicine · Nature · NYSE:NVO · Science

COVID Booster Shocker, Pharma Mega-Deals & Alzheimer’s Breakthroughs – Global Health Roundup (Aug 28–29, 2025)

Drug Approvals & Clinical Trial Results Updated COVID Boosters Get Narrow Nod: The U.S. FDA approved new fall COVID-19 booster shots from Pfizer/BioNTech and Moderna on August 27 – but with strict eligibility limits. Only adults 65+ and younger people

29 August 2025

COVID-19 · Global Health · Health News · Medical Breakthroughs · NASDAQ:AMLX · NASDAQ:OTLK · NASDAQ:PRTA · NYSE:NVO · NYSE:WBA · Pharmaceuticals

Game-Changing Vaccines, Breakthrough Drugs, and a CDC Shakeup: Biotech & Health News Roundup

In-Depth Report COVID-19 Vaccines and U.S. Public Health Upheaval Targeted Fall Boosters, But Access Tightened: U.S. health authorities approved new monovalent COVID-19 vaccines (by Pfizer–BioNTech, Moderna, and Novavax) updated for the 2025–26 season reuters.com. Unlike prior booster rollouts, the FDA

28 August 2025

Biotechnology · CDC · Health · Medicine · NASDAQ:JAZZ · NYSE:GSK · NYSE:LLY · NYSE:NVO · Vaccines

Breakthrough Cures, Billion-Dollar Bets & Health Shockers – Global Biotech & Health News Roundup (Aug 23–24, 2025)

Regulatory Approvals & Clinical Milestones Pharma & Biotech Industry Moves Startups & Innovation Highlights ([…Placeholder – if needed, otherwise this section can be omitted due to a lack of specific startup news on Aug 23–24 beyond the AI deal covered

24 August 2025

Biotech · Global Health · Healthcare · Investments · Medical Breakthroughs · NASDAQ:DVAX · NASDAQ:RCKT · NYSE:GSK · NYSE:NVO

Biotech Breakthroughs & Pharma Shakeups – Global Health Roundup (Aug 20–21, 2025)

Industry & Corporate Developments Mergers, Acquisitions & Partnerships Regulatory & Drug Approval Updates Public Health & Policy Research & Clinical Breakthroughs Sources: Reuters, Politico, HealthLeaders, BioPharma Dive, FierceBiotech, Pharmaceutical Executive, Technology Networks, McGill University reuters.com reuters.com healthleadersmedia.com reuters.com fiercebiotech.com reuters.com

21 August 2025

Biotech · Healthcare · Industry News · Medical Innovations · NASDAQ:CRL · NYSE:LLY · NYSE:MDT · NYSE:NVO · NYSE:PFE · NYSE:TAK · Pharmaceuticals

Tariff Tsunami, Tech Tumble & Peace Talk Buzz – Global Business Roundup (Aug 19–20, 2025)

Nvidia shares plunged on August 19, 2025, as part of a tech-led market selloff that dragged the Nasdaq about 1.5% lower. Futures priced in at least two 25-basis-point Fed rate cuts by year-end, while the U.S. 10-year yield eased to

20 August 2025

Economics · Global Business · International Relations · NASDAQ:GOOG · NASDAQ:INTC · NASDAQ:NVDA · NASDAQ:NXST · NASDAQ:TSLA · NYSE:LLY · NYSE:NVO · NYSE:TGNA · Technology · Trade

Biotech, Pharma, and Health Breakthroughs You Missed on August 17–18, 2025

New Drug Approvals & Clinical Trial Results Mergers, Acquisitions & Partnerships (No other major M&A deals were announced during Aug 17–18, but this Lilly-Superluminal alliance highlights the continued investment in AI-driven R&D.) Regulatory & Policy Updates Public Health & Epidemiology

18 August 2025

Biotech · Health · Medical News · NASDAQ:GBT · NASDAQ:MDGL · NASDAQ:TNXP · NYSE:NVO · NYSE:PFE · Pharma · Research

NYSE:NVO News 18 August 2025 - 6 October 2025